Core Viewpoint - Quoin Pharmaceuticals Ltd. has achieved significant milestones with its NETHERTON NOW awareness campaign, which has garnered over one million video views and more than 14 million impressions, highlighting the realities of Netherton Syndrome [1][2][3] Company Overview - Quoin Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing treatments for rare and orphan diseases, with a commitment to addressing unmet medical needs [5] - The company is advancing its lead investigational candidate, QRX003, through late-stage clinical trials for Netherton Syndrome, with full enrollment expected in early to mid-Q1 2026 [3][4] Campaign Details - The NETHERTON NOW campaign aims to amplify the voices of patients, families, and experts, raising awareness and education about Netherton Syndrome [2][4] - The campaign has been widely circulated on social media and featured in major outlets, including MSN, Today, and CBS News, as well as clinical publications [2] Clinical Development - QRX003 is being studied as both a monotherapy and in combination with off-label systemic treatments, with early data showing encouraging signals [3][4] - The ongoing initiative seeks to improve education and elevate the voices of those affected by Netherton Syndrome, reinforcing the company's commitment to advancing meaningful therapies [4]

Core Insights - Quoin Pharmaceuticals has released the second episode of its "Living with Netherton" video series, featuring the story of 79-year-old Norma Coles, who was diagnosed with Netherton Syndrome decades after her initial evaluation [1][2] - The campaign aims to raise awareness and support for individuals affected by Netherton Syndrome, highlighting the challenges faced by patients, including misdiagnosis and lack of treatment options [2][4] - Quoin's lead product candidate, QRX003, is currently undergoing clinical trials, with the goal of becoming the first FDA-approved treatment for Netherton Syndrome [5][6] Company Overview - Quoin Pharmaceuticals is a late clinical-stage specialty pharmaceutical company focused on developing treatments for rare and orphan diseases [1][7] - The company has a pipeline that includes four products targeting various rare conditions, including Netherton Syndrome, Peeling Skin Syndrome, and others [7] - Quoin is committed to addressing unmet medical needs and improving the quality of life for patients and their families [7] Product Development - QRX003 is a topical lotion designed to address the skin barrier issues associated with Netherton Syndrome by promoting a normalized skin-shedding process [6] - Initial data from ongoing clinical trials of QRX003 show promising results, including improvements in skin healing and reductions in inflammation and pruritus [5] - The company aims to complete the development of QRX003 to provide a transformative treatment option for patients who have long awaited effective therapies [5][6]

Core Insights - Quoin Pharmaceuticals has released the second episode of its "Living with Netherton" video series, featuring a 79-year-old patient, Norma Coles, who has lived with Netherton Syndrome for decades, highlighting the need for awareness and treatment [1][2][4] - The company aims to raise awareness and improve education regarding Netherton Syndrome, which currently has no FDA-approved treatment, emphasizing the urgency for effective therapeutic options [2][5] Company Overview - Quoin Pharmaceuticals is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products for rare and orphan diseases [1][7] - The company is committed to addressing unmet medical needs and has a pipeline that includes four products targeting various rare conditions, including Netherton Syndrome [7] Product Development - Quoin's lead product candidate, QRX003, is currently undergoing evaluation in four clinical trials for the treatment of Netherton Syndrome, with initial data showing improvements in skin healing and quality of life [5][6] - QRX003 is a topical lotion designed to normalize skin-shedding processes and strengthen the skin barrier, addressing the underlying issues of Netherton Syndrome [6] Campaign and Advocacy - The NETHERTON NOW campaign is central to Quoin's efforts to raise awareness and support for individuals affected by Netherton Syndrome, sharing real patient experiences to foster understanding [4][5] - The company emphasizes the importance of patient stories, like that of Norma Coles, to illustrate the challenges faced by those living with this rare genetic disorder [2][5]